Header Logo

Adam S Duerfeldt

TitleAssistant Professor
InstitutionUniversity of Oklahoma, Norman
DepartmentChemistry/Biochemistry
Address620 Parrington Oval
Norman OK 73019
Phone405/325-4812
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21EY028279     (DUERFELDT, ADAM SCOTT)Sep 1, 2017 - Aug 31, 2019
    NIH
    Hit to Lead Optimization of a Systemically Available Treatment for Diabetic Retinopathy
    Role: Principal Investigator

    R01EY030472     (DUERFELDT, ADAM SCOTT)May 1, 2020 - Apr 30, 2025
    NIH
    Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dou X, Duerfeldt AS. Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. Int J Mol Sci. 2020 Dec 04; 21(23). PMID: 33291567.
      Citations:    Fields:    Translation:HumansAnimals
    2. Dou X, Nath D, Shin H, Nurmemmedov E, Bourne PC, Ma JX, Duerfeldt AS. Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARa Agonists as Leads for Retinal Disorders. J Med Chem. 2020 03 26; 63(6):2854-2876. PMID: 32096640.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    3. Li Y, Gardner JJ, Fortney KR, Leus IV, Bonifay V, Zgurskaya HI, Pletnev AA, Zhang S, Zhang ZY, Gribble GW, Spinola SM, Duerfeldt AS. First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitors. Bioorg Med Chem Lett. 2019 07 15; 29(14):1836-1841. PMID: 31104993.
      Citations: 5     Fields:    Translation:HumansAnimals
    4. Lavey NP, Shadid T, Ballard JD, Duerfeldt AS. Clostridium difficile ClpP Homologues are Capable of Uncoupled Activity and Exhibit Different Levels of Susceptibility to Acyldepsipeptide Modulation. ACS Infect Dis. 2019 01 11; 5(1):79-89. PMID: 30411608.
      Citations: 6     Fields:    Translation:Cells
    5. Dou XZ, Nath D, Shin Y, Ma JX, Duerfeldt AS. Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARa selective agonists: New leads for oculovascular conditions. Bioorg Med Chem Lett. 2018 09 01; 28(16):2717-2722. PMID: 29628329.
      Citations: 3     Fields:    Translation:HumansCells
    6. Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. J Med Chem. 2018 04 12; 61(7):2793-2805. PMID: 29528635.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    7. Li Y, Lavey NP, Coker JA, Knobbe JE, Truong DC, Yu H, Lin YS, Nimmo SL, Duerfeldt AS. Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides. ACS Med Chem Lett. 2017 Nov 09; 8(11):1171-1176. PMID: 29152050.
      Citations:    
    8. Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL, Lieberman RL, Dickey CA, Blagg BS. Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. J Med Chem. 2016 Apr 14; 59(7):3471-88. PMID: 27003516.
      Citations: 20     Fields:    Translation:HumansCells
    9. Lavey NP, Coker JA, Ruben EA, Duerfeldt AS. Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P. J Nat Prod. 2016 Apr 22; 79(4):1193-7. PMID: 26967980.
      Citations: 7     Fields:    Translation:Cells
    10. Di XJ, Wang YJ, Han DY, Fu YL, Duerfeldt AS, Blagg BS, Mu TW. Grp94 Protein Delivers ?-Aminobutyric Acid Type A (GABAA) Receptors to Hrd1 Protein-mediated Endoplasmic Reticulum-associated Degradation. J Biol Chem. 2016 Apr 29; 291(18):9526-39. PMID: 26945068.
      Citations: 10     Fields:    Translation:HumansCells
    11. Anderson ED, Duerfeldt AS, Zhu K, Glinkerman CM, Boger DL. Cycloadditions of noncomplementary substituted 1,2,3-triazines. Org Lett. 2014 Oct 03; 16(19):5084-7. PMID: 25222918.
      Citations: 8     Fields:    Translation:Cells
    12. Duerfeldt AS, Boger DL. Total syntheses of (-)-pyrimidoblamic acid and P-3A. J Am Chem Soc. 2014 Feb 05; 136(5):2119-25. PMID: 24410439.
      Citations: 10     Fields:    Translation:Cells
    13. Wolfe AL, Duncan KK, Lajiness JP, Zhu K, Duerfeldt AS, Boger DL. A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. J Med Chem. 2013 Sep 12; 56(17):6845-57. PMID: 23944748.
      Citations: 4     Fields:    Translation:AnimalsCells
    14. Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BS, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. J Biol Chem. 2012 Nov 23; 287(48):40661-9. PMID: 23035116.
      Citations: 32     Fields:    Translation:HumansCells
    15. Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. J Am Chem Soc. 2012 Jun 13; 134(23):9796-804. PMID: 22642269.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    16. Kusuma BR, Duerfeldt AS, Blagg BS. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett. 2011 Dec 01; 21(23):7170-4. PMID: 22014546.
      Citations: 6     Fields:    Translation:HumansCells
    17. Duerfeldt AS, Blagg BS. Hsp90 inhibition: elimination of shock and stress. Bioorg Med Chem Lett. 2010 Sep 01; 20(17):4983-7. PMID: 20656483.
      Citations: 10     Fields:    Translation:Cells
    18. Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett. 2009 Dec 15; 19(24):6845-50. PMID: 19896848.
      Citations: 1     Fields:    Translation:HumansCells
    19. Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett. 2009 Jun 04; 11(11):2353-6. PMID: 19435295.
      Citations: 10     Fields:    Translation:HumansCells
    20. Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. ACS Chem Biol. 2009 Apr 17; 4(4):245-7. PMID: 19371133.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    Duerfeldt's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (114)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _